127 related articles for article (PubMed ID: 8418157)
1. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis.
Cross AS; Opal SM; Palardy JE; Bodmer MW; Sadoff JC
J Infect Dis; 1993 Jan; 167(1):112-8. PubMed ID: 8418157
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis.
Opal SM; Cross AS; Sadoff JC; Collins HH; Kelly NM; Victor GH; Palardy JE; Bodmer MW
J Clin Invest; 1991 Sep; 88(3):885-90. PubMed ID: 1885775
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.
Opal SM; Cross AS; Kelly NM; Sadoff JC; Bodmer MW; Palardy JE; Victor GH
J Infect Dis; 1990 Jun; 161(6):1148-52. PubMed ID: 2140582
[TBL] [Abstract][Full Text] [Related]
4. Potential hazards of combination immunotherapy in the treatment of experimental septic shock.
Opal SM; Cross AS; Jhung JW; Young LD; Palardy JE; Parejo NA; Donsky C
J Infect Dis; 1996 Jun; 173(6):1415-21. PubMed ID: 8648214
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis.
Romulo RL; Palardy JE; Opal SM
J Infect Dis; 1993 Jan; 167(1):126-30. PubMed ID: 8418159
[TBL] [Abstract][Full Text] [Related]
6. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
Calandra T; Baumgartner JD; Glauser MP
Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime.
Akiyama M; Oishi K; Tao M; Matsumoto K; Pollack M
Microbiol Immunol; 2000; 44(8):629-35. PubMed ID: 11021392
[TBL] [Abstract][Full Text] [Related]
8. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.
Silva AT; Bayston KF; Cohen J
J Infect Dis; 1990 Aug; 162(2):421-7. PubMed ID: 2373872
[TBL] [Abstract][Full Text] [Related]
10. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock.
Suitters AJ; Foulkes R; Opal SM; Palardy JE; Emtage JS; Rolfe M; Stephens S; Morgan A; Holt AR; Chaplin LC
J Exp Med; 1994 Mar; 179(3):849-56. PubMed ID: 8113678
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
13. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
Fisher CJ; Opal SM; Dhainaut JF; Stephens S; Zimmerman JL; Nightingale P; Harris SJ; Schein RM; Panacek EA; Vincent JL
Crit Care Med; 1993 Mar; 21(3):318-27. PubMed ID: 8440099
[TBL] [Abstract][Full Text] [Related]
14. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.
Pennington JE; Small GJ; Lostrom ME; Pier GB
Infect Immun; 1986 Oct; 54(1):239-44. PubMed ID: 3093385
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas immunoglobulin therapy in patients with Pseudomonas sepsis and septic shock.
Pilz G; Class I; Boekstegers P; Pfeifer A; Müller U; Werdan K
Antibiot Chemother (1971); 1991; 44():120-35. PubMed ID: 1801630
[No Abstract] [Full Text] [Related]
16. [Immunotherapy of sepsis and septic shock].
Ivanović D; Gjurasin M; Gasparović V; Radonić R; Kvarantan M; Merkler M
Lijec Vjesn; 1995 Jun; 117 Suppl 2():8-11. PubMed ID: 8649167
[TBL] [Abstract][Full Text] [Related]
17. Release of endothelin in relation to tumor necrosis factor-alpha in porcine Pseudomonas aeruginosa-induced septic shock.
Han JJ; Windsor A; Drenning DH; Leeper-Woodford S; Mullen PG; Bechard DE; Sugerman HJ; Fowler AA
Shock; 1994 May; 1(5):343-6. PubMed ID: 7743336
[TBL] [Abstract][Full Text] [Related]
18. Therapy with antibody to tumor necrosis factor in sepsis.
Pennington JE
Clin Infect Dis; 1993 Nov; 17 Suppl 2():S515-9. PubMed ID: 8274618
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients.
Saravolatz LD; Markowitz N; Collins MS; Bogdanoff D; Pennington JE
J Infect Dis; 1991 Oct; 164(4):803-6. PubMed ID: 1910070
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa. Vaccines and immunotherapy.
Pennington JE
Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
